Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04471727
Title A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
Acronym MK-6070-001/HPN328-4001
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.